BioXcel Therapeutics (BTAI) Equity Average (2018 - 2026)

BioXcel Therapeutics' Equity Average history runs 9 years deep, the most recent figure standing at -$100.5 million for Q1 2026.

• In Q1 2026, Equity Average fell 9.68% year-over-year to -$100.5 million; the TTM figure through Mar 2026 stood at -$100.5 million (down 9.68% YoY), while the FY2025 annual figure was -$94.3 million, down 26.04% from the prior year.
• Equity Average was -$100.5 million for Q1 2026 at BioXcel Therapeutics, down from -$92.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $207.8 million in Q1 2022 to a low of -$100.5 million in Q1 2026.
• Historically, Equity Average has averaged -$7.4 million across 5 years, with a median of -$64.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Equity Average gained 5.66% in 2022, then tumbled 360.32% in 2024.
• A 5-year view of Equity Average shows it stood at $101.9 million in 2022, then plunged by 147.66% to -$48.6 million in 2023, then slumped by 84.04% to -$89.4 million in 2024, then decreased by 3.16% to -$92.2 million in 2025, then slipped by 9.02% to -$100.5 million in 2026.
• The last three Equity Average figures came in at -$100.5 million (Q1 2026), -$92.2 million (Q4 2025), and -$98.3 million (Q3 2025), per Business Quant data.